Published On: Wed, Oct 19th, 2016

Lion Biotechnologies Inc (LBIO) Updated Analyst Coverage


A number of investment brokers have recently updated their price targets on shares of Lion Biotechnologies Inc (LBIO).

Most recent broker ratings

08/25/2016 – Lion Biotechnologies Inc had its “buy” rating reiterated by analysts at Roth Capital. They now have a USD 15 price target on the stock.

06/06/2016 – Lion Biotechnologies Inc was downgraded to “neutral” by analysts at SunTrust. They now have a USD 30.5 price target on the stock.

12/21/2015 – Lion Biotechnologies Inc had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 20 price target on the stock.

06/30/2015 – Lion Biotechnologies Inc had its “outperform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 20 price target on the stock.

06/03/2015 – Lion Biotechnologies Inc had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 18 price target on the stock.

03/09/2015 – Piper Jaffray began new coverage on Lion Biotechnologies Inc giving the company a “overweight” rating. They now have a USD 21 price target on the stock.

06/30/2014 – Laidlaw began new coverage on Lion Biotechnologies Inc giving the company a “buy” rating.

The share price of Lion Biotechnologies Inc (LBIO) was up +0.00% during the last day of trading, with a day high of 6.50. 130485 shares were traded during the last session.

The stock’s 50 day moving average is 7.81 and its 200 day moving average is 7.37. The stock’s market capitalization is 373.99M. Lion Biotechnologies Inc has a 52-week low of 4.24 and a 52-week high of 9.58.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The Company develops a portfolio of TIL-based products for the treatment of solid tumors. In addition to LN-144, the Company intends to develop additional TIL-based pipeline products to treat a range of solid tumors. It develops LN-145 to treat cervical and head and neck cancers. TIL therapy involves growing a patient’s TIL in special culture conditions outside the patient’s body, or ex vivo, and then infusing the T cells back into the patient in combination with interleukin-2 (IL-2).